Health Check: For bloodied CSL, the horror continues

For the battered and bloodied CSL, the problems look like getting worse before things get better. Pic: Getty Images.

Despite “green shoots” of recovery, CSL’s earnings officially are going backwards
Emvision eyes a two-year time saving with expanded pivotal stroke trial
Now out of favour with Trump, Marty Makary is polishing off his CV

 

In today’s thumping profit downgrade, blood and plasma giant CSL (ASX:CSL) admits its current year earnings will go backwards, as management strives to right the listing ship.

Despite the company’s woes, management in February pointed to underlying net profit advancing 4-7%.

Now it looks like earnings for the year to June 30 2025 will retreat around 4%.

Concerningly, the core Behring arm faces improved competitor capacity that has boosted excess plasma supply.

This problem appears to be structural, rather than cyclical.

Investors slashed CSL shares by as much as 20%, pushing them below the $100 mark for the first time in ten years.

“We fully recognise that CSL’s financial outcomes have fallen short of expectations,” interim CEO Gordon Naylor said.

He said the company’s US$32 billion ($44bn) of invested capital clearly was not all “working as hard as it should be”.

Naylor said management’s growth medicine was helping, “but the financial benefits will take longer than previously anticipated to materialise”.

The company said immunoglobulin demand in its core US market was growing at mid to high single digits, consistent with CSL’s expectations.

But the reported revenue will reflect CSL’s “normalisation of channel inventory”.

In other words, there was too much stuff in the system.

 

What’s the damage?

CSL now expects full-year revenue of US$15.2 billion, around 2% lower and net profit after tax and amortisation (NPATA) of US$3.1bn (4% lower).

This is on a ‘constant currency’ basis. Taking “volatile” currencies into account, revenue will come in US$400m higher, while NPATA  will be a modest US$30m lower.

But management always has nominated constant currency as its preferred measure.

The immunoglobulin problem is expected to result in a US$300m revenue hit.

Turnover will decline by a further US$200m because of the declining value of the Chinese albumin market (despite CSL’s expanding share).

And did anyone mention the Middle East conflict?

The conflagration will erase US$150m of revenue from the iron side of the business and CSL’s haemophilia treatment Hemgenix.

 

Green shoots among the weeds

More positively note, management reports “green shoots”, including “improvements in end-patient demand and momentum across recent product launches”.

Behring’s second half volumes have grown, although gross margins have “degraded”.

The performance of CSL’s flu vaccine arm also has been “moderately stronger than previously anticipated”.

On Behring, Naylor said the industry was “stable and growing and the company has evident strengths in plasma collections and influenza vaccines”.

Naylor said CSL remained “very profitable”, with “metronomic” cash flows and significant financial capacity.

“I can also say that CSL continues to have evident competitive strengths in plasma collection and influenza vaccines.”

In its transformation program already announced, CSL expects ongoing annual cost savings of US$500-550m.

CSL today also flagged US$5bn of non-cash asset impairments over the next two years, US$1.5bn of which was recognised in the December 2025 (first) half.

 

Emvision expands its stroke trial remit

The developer of a portable stroke detection unit, EMvision Medical Devices (ASX:EMV) has expanded its pivotal trial to the dominant majority of strokes.

The study will now test the ability of the company’s Emu device to detect acute ischaemic strokes (blockages). This is opposed to the original remit of identifying haemorrhagic strokes (bleeds).

“An ischaemia detection feature extends the device’s clinically actionable use case in the dominant majority (around 80%) of stroke presentations,” the company said.

“Because ischaemic stroke interventions (clot dissolving drugs and clot retrieval) are highly time-dependent, the ability to rapidly identify ischaemia at the bedside has the potential to meaningfully reduce intervention delays and improve patient outcomes.”

The company said acute ischaemic stroke detection is widely recognised as a more complex clinical and technical problem than haemorrhage detection.

This was especially the case in “hyperacute window and in care settings where advanced multimodal neuroimaging is not immediately available”.

Meanwhile, the company says the Emu trial is up and striding across eight US and Australian hospitals, with more 125 patients enrolled so far.

“The device continues to integrate seamlessly into hospital code stroke workflows, with no device-related adverse events reported.”

The company intends to engage with the FDA on the proposed expanded endpoints, which will avail of the same patients and infrastructure.

Management believes its approach could save up to two years and many millions of dollars,  relative to carrying out a standalone ischaemia trial later on.

 

Pacific Edge raises funds amid deeper losses

Bladder cancer test developer Pacific Edge (ASX:PEB) is doing the rounds to raise $NZ24 million ($19.6m) in a placement and retail issue.

Pacific Edge has been tussling with US reimbursement gatekeepers over coverage of its Cxbladder assay.

Thus, the funding is to ensure Pacific Edge has the “resources and capacity” to regain the crucial US Medicare coverage and “position the business for growth”.

The placement seeks to raise $NZ18m with a further $NZ6m from the retail stanza which is akin to a share purchase plan.

Both are priced at NZ17 cents a share, a modest 2.3% discount to today’s frozen price.

Ahead of its May 26 full year result, Pacific Edge also said the coverage removal resulted in revenue falling to $NZ11.5 million, from $NZ21.8m previously.

This increased the net loss to NZ$35.7m, from NZ$29.9m previously.

 

Dead man walking at FDA

According to multiple US reports, President Trump will fire his choice pick as head of the FDA on Monday.

It looks like FDA Commissioner Marty Makary offended too many parties, ranging from vaping advocates, the anti-abortion lobby and Big Pharma.

Trump reportedly ticked off Makary for refusing to approve fruit-flavored vapes.

Most interestingly, Makary appears to have gone too far on the anti-vaccine front by blocking material showing shingles and Covid vaccines to be safe.

Throw in concerns about a proposed easier drug approval approval route from two late-stage clinical studies to one and Makary’s job looks as safe as Keir Starmer’s.

At least some Australian biotech figures thought the agency had settled down since Trump’s early days. But it looks like still waters run deep.

 

 

At Stockhead we tell it as it is. While Emvision is a Stockhead advertiser, the company did not sponsor this article.